The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.
about
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitorsLarge scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia AItalian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis.Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin.The cost of severe haemophilia in Europe: the CHESS study.HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.A zymogen-like factor Xa variant corrects the coagulation defect in hemophiliaPrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyThe Epidemiology of FVIII Inhibitors in Indian Haemophilia A PatientsInhibitors in previously treated patients: a review of the literatureConsensus review of the treatment of cardiovascular disease in people with hemophilia A and B.A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cellsCost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in IranTreatment of hemophilia: a review of current advances and ongoing issuesSuccessful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia.Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors.Therapy for haemophilia: recent advances and goals for the future.Haemophilia B: Christmas disease.Genetic diagnosis of haemophilia and other inherited bleeding disorders.Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience.Strategies to target long-lived plasma cells for treating hemophilia A inhibitors.International workshop on immune tolerance induction: consensus recommendations.Inhibitor development in haemophilia B: an orphan disease in need of attention.Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.The management of hemophilia in elderly patients.Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature.High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance.Ethical considerations in clinical investigation: exploring relevance in haemophilia research.A survey of the management of newborns with severe hemophilia in Canada.Bone density in haemophilia: a single institutional cross-sectional study.Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor MiceThe history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review.Immunomodulation for inhibitors in hemophilia A: the important role of Treg cellsPharmacotherapy of haemophilia A.Surgery and inhibitor development in hemophilia A: a systematic review.Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.
P2860
Q24187021-FD14A0D9-FB6F-4F9C-A131-08B5B3872E01Q30234910-C5F91204-00C9-4526-AC8C-889E7F7392AAQ30539581-9746336B-0210-41FA-852E-29A5AECA3039Q33324733-DE339C0D-A059-4051-B41D-D1A7B96E1B1CQ33394560-5B1EEBCD-A431-4A41-AFCB-0844647E6F70Q33750095-3B014327-DC2B-4B76-9E44-3718EDEFC614Q33910694-0157DE16-65C3-4F40-A6B1-A7D23A89B54BQ34149960-44CAB65E-5777-44B8-96BC-4C8DDD554E91Q34416394-277431ED-15E8-46FD-9F4F-0180C8A5D399Q34569046-199F38CF-8F48-4426-824E-8BA052E8F12CQ34777714-E2A3EC00-7CFC-4821-84F4-759402197BD6Q35069871-D23D7D3E-DEE5-4F5F-BEB4-CB9C5B4B17E7Q35176160-AF7317F8-2221-4E99-BE54-9960B950B23BQ35285735-D9F0971E-BCEE-475D-B2A6-5EFCFD13D731Q35602600-B039A55E-0C74-4B62-A1C9-6807DCD31F04Q35683781-8E501428-2EFB-4178-89C0-A0AE34138E35Q35910932-C5C0B88F-0384-4A8F-9B90-C05AA232CB5BQ36019034-996E513E-DE54-45C7-AB2B-03558611250AQ36066048-0854E73A-E136-402D-BAB1-15DC740A2E44Q36221979-F388F6B8-5253-4804-8F2E-049E954920ACQ36473065-E4A88724-A23D-42C7-914D-52637ED0425DQ36643868-322653C6-1055-4613-982E-620D122CDE4CQ36819965-558F0EF9-B753-446E-8C31-11EE1E396A92Q36832899-E15E4DC4-3EAE-483C-9341-E5F1C7D2D0CFQ36861097-EA52574E-53F9-4784-A310-42B2110799AEQ36872038-79037B19-FC66-4425-B1EF-8E521AC290D0Q36985329-5A4BA00A-958A-4D77-9F74-41C80361808EQ37017437-0622CF48-D74D-4EBE-919A-5597F17B14C7Q37032862-2DFC8479-153B-4F53-82E8-157617F83D16Q37153668-1910DB8B-4639-4AF0-A911-D672B6EA6759Q37176526-90D10CBD-0212-40BD-B243-8311629EDF11Q37248441-E0E65177-BDE5-439F-847F-6005A37DE662Q37361086-8273A16C-B05D-46BF-BB21-54BF1D739F64Q37365186-BB5949C6-DB7E-4F8F-A608-43E4BC78CE40Q37434315-DDFBCFD7-CA49-4981-9770-18369542E040Q37578173-53FE4CBA-3890-48ED-9B58-9B2CA28705F6Q37803130-8DF41B55-1E7D-420C-AC88-94CF3D334DB0Q37891089-3BF82A31-4B48-402A-A58B-CC48660D84B8Q37916686-793EAC0F-F016-4F3A-9630-DD8697211FC1Q37977140-F404289A-AFAA-4C8F-87F9-E66FB55D751E
P2860
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The incidence of factor VIII a ...... subsequent mortality, 1977-99.
@en
The incidence of factor VIII a ...... subsequent mortality, 1977-99.
@nl
type
label
The incidence of factor VIII a ...... subsequent mortality, 1977-99.
@en
The incidence of factor VIII a ...... subsequent mortality, 1977-99.
@nl
prefLabel
The incidence of factor VIII a ...... subsequent mortality, 1977-99.
@en
The incidence of factor VIII a ...... subsequent mortality, 1977-99.
@nl
P2093
P921
P1476
The incidence of factor VIII a ...... subsequent mortality, 1977-99
@en
P2093
F G H Hill
P L F Giangrande
P W Collins
R J D Spooner
UK Haemophilia Centre Doctors' Organisation
P2860
P304
P356
10.1046/J.1538-7836.2004.00710.X
P577
2004-07-01T00:00:00Z